Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

SELLAS Life Sciences (SLS) Income from Continuing Operations (2020 - 2024)

SELLAS Life Sciences (SLS) has disclosed Income from Continuing Operations for 8 consecutive years, with 6737000.0 as the latest value for Q4 2024.

  • Quarterly Income from Continuing Operations rose 17.2% to 6737000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was 30881000.0 through Dec 2024, up 17.71% year-over-year, with the annual reading at 26863000.0 for FY2025, 13.01% up from the prior year.
  • Income from Continuing Operations for Q4 2024 was 6737000.0 at SELLAS Life Sciences, up from 7108000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 2245000.0 in Q1 2021, with the low at 16735000.0 in Q1 2022.
  • Average Income from Continuing Operations over 5 years is 7631650.0, with a median of 7308000.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations surged 44.76% in 2021, then plummeted 645.43% in 2022.
  • Over 5 years, Income from Continuing Operations stood at 4159000.0 in 2020, then tumbled by 179.37% to 11619000.0 in 2021, then increased by 18.7% to 9446000.0 in 2022, then increased by 13.87% to 8136000.0 in 2023, then rose by 17.2% to 6737000.0 in 2024.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 6737000.0, 7108000.0, and 7470000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.